Header Logo

Connection

MALCOLM BRENNER to Middle Aged

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Middle Aged.
MALCOLM BRENNER
Connection Strength
0.490
Middle Aged
  1. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
    View in: PubMed
    Score: 0.036
  2. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.031
  3. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39.
    View in: PubMed
    Score: 0.024
  4. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72.
    View in: PubMed
    Score: 0.022
  5. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
    View in: PubMed
    Score: 0.017
  6. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23.
    View in: PubMed
    Score: 0.016
  7. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
    View in: PubMed
    Score: 0.016
  8. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
    View in: PubMed
    Score: 0.015
  9. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
    View in: PubMed
    Score: 0.015
  10. Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
    View in: PubMed
    Score: 0.015
  11. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894.
    View in: PubMed
    Score: 0.015
  12. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.012
  13. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.012
  14. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001 Jan; 27(1):117-20.
    View in: PubMed
    Score: 0.012
  15. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
    View in: PubMed
    Score: 0.011
  16. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.010
  17. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.010
  18. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
    View in: PubMed
    Score: 0.010
  19. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.009
  20. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
    View in: PubMed
    Score: 0.009
  21. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.009
  22. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.008
  23. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.007
  24. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.007
  25. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.007
  26. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.007
  27. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol. 1992 Jun; 81(2):231-4.
    View in: PubMed
    Score: 0.006
  28. IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
    View in: PubMed
    Score: 0.006
  29. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.006
  30. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44.
    View in: PubMed
    Score: 0.006
  31. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 01; 172(6):1729-34.
    View in: PubMed
    Score: 0.006
  32. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
    View in: PubMed
    Score: 0.006
  33. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505.
    View in: PubMed
    Score: 0.006
  34. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80.
    View in: PubMed
    Score: 0.005
  35. Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6.
    View in: PubMed
    Score: 0.005
  36. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
    View in: PubMed
    Score: 0.005
  37. Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
    View in: PubMed
    Score: 0.005
  38. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.005
  39. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34.
    View in: PubMed
    Score: 0.005
  40. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
    View in: PubMed
    Score: 0.005
  41. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.005
  42. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.004
  43. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.004
  44. Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):125-32.
    View in: PubMed
    Score: 0.004
  45. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
    View in: PubMed
    Score: 0.004
  46. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
    View in: PubMed
    Score: 0.004
  47. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
    View in: PubMed
    Score: 0.004
  48. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
    View in: PubMed
    Score: 0.003
  49. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
    View in: PubMed
    Score: 0.003
  50. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
    View in: PubMed
    Score: 0.002
  51. Concentric sclerosis (Bal?): morphometric and in situ hybridization study of lesions in six patients. Ann Neurol. 1994 Jan; 35(1):18-30.
    View in: PubMed
    Score: 0.002
  52. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant. 1991 Jul; 8(1):19-26.
    View in: PubMed
    Score: 0.001
  53. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5.
    View in: PubMed
    Score: 0.001
  54. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol. 1989 Feb; 27(2):117-9.
    View in: PubMed
    Score: 0.001
  55. Expression of tartrate-resistant acid phosphatase in B-CLL treated with phorbol ester or phorbol ester plus calcium ionophore. Eur J Haematol. 1988 Sep; 41(3):250-7.
    View in: PubMed
    Score: 0.001
  56. Differential expression of MHC class II antigens in chronic B-cell disorders. Clin Exp Immunol. 1988 Feb; 71(2):217-23.
    View in: PubMed
    Score: 0.001
  57. CD5-positive B cells after T cell depleted bone marrow transplantation. Clin Exp Immunol. 1987 Jun; 68(3):662-8.
    View in: PubMed
    Score: 0.001
  58. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone Marrow Transplant. 1987 Apr; 1(4):347-55.
    View in: PubMed
    Score: 0.001
  59. T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol. 1986 Mar; 63(3):577-86.
    View in: PubMed
    Score: 0.001
  60. Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
    View in: PubMed
    Score: 0.001
  61. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986 Feb 15; 1(8477):339-43.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.